Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Study Details
Study Description
Brief Summary
Topical insulin application has been proved recently to increase corneal reepithelization rate over diabetic animals. However, its effectiveness on corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy and penetrating keratoplasty has not been reported. In this study, we plan to perform a prospective randomized study to determine the effectiveness of topical insulin as a primary treatment for corneal epithelial defect in patients undergoing vitrectomy for diabetic retinopathy and penetrating keratoplasty. All patients enrolled in this study have received corneal epithelial debridement at the end of the ocular surgeries, namely PPV for diabetic retinopathy and penetrating keratoplasty. The patients were randomized into two treatment groups. In the control group, the patients receive conventional postoperative eye drops including topical steroid, antibiotic and mydriatics. In the experimental group, the patients receive topical insulin eye drops in addition to conventional postoperative eye drops. The duration for the corneal surface to completely re-epithelize, the incidence of corneal complications due to delayed surface re-epithelization (e.g. infectious corneal ulcer, corneal melting, sterile corneal ulcer, corneal neovascularization), and the incidence of recurrent epithelial break down after initial epithelization will be compared between these two groups. Patients undergoing PPV for diabetic retinopathy and penetrating keratoplasty will be compared separately.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Purpose: To evaluate the treatment effects of topical insulin eye drops for promoting corneal epithelium wound healing in patients receiving pars planar vitrectomy (PPV) for diabetic retinopathy and penetrating keratoplasty.
Background: During PPV for diabetic retinopathy retinopathy and penetrating keratoplasty, removal of the edematous corneal epithelial layer was usually required in order to obtain a better surgical view1 or enhance the postoperative epithelial wound healing process. However, delayed epithelial healing was frequently found in these patients after surgeries. In addition, corneal epithelial defect is also frequent found in diabetic patients after PPV even corneal epithelial debridement is not performed during the operation. Topical insulin application has been known to increase corneal reepithelization rate over diabetic animals, has is known to have no influence on systemic glucose level in humans and animals. In this study, we plan to perform a prospective randomized study to determine the effectiveness of topical insulin eye drops as a primary treatment in corneal epithelial defect following vitrectomy in diabetic patients and penetrating keratoplasty.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: 1 Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy receiving topical insulin eye drops in addition to conventional postoperative eye drops |
Drug: Topical insulin eye drops
Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
|
| Active Comparator: 2 Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving topical insulin eye drops in addition to conventional postoperative eye drops |
Drug: Topical insulin eye drops
Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
|
| Placebo Comparator: 3 Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy treated with conventional postoperative eye drops |
Drug: Conventional postoperative eye drops
topical steroid, antibiotic and mydriatics
|
| Placebo Comparator: 4 corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving conventional postoperative eye drops |
Drug: Conventional postoperative eye drops
topical steroid, antibiotic and mydriatics
|
Outcome Measures
Primary Outcome Measures
- Duration for the corneal surface to completely re-epithelize [1week, 2 weeks, 1 month, 2 month, 3 month, 6 month]
Secondary Outcome Measures
- Incidence of corneal complications due to delayed surface re-epithelization (e.g. infectious corneal ulcer, corneal melting, sterile corneal ulcer, corneal neovascularization) [1 week, 2 weeks, 1 month, 2 month, 3 month, 6 month]
- Incidence of recurrent epithelial break down after initial epithelization [1 week, 2 weeks, 1 month, 2 month, 3 month, 6 month]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diabetic patients with proliferative retinopathy receiving PPV
-
Patients qualified for penetrating keratoplasty
-
DM control blood sugar AC < 200mg/dl
-
no limbus defect
-
no glaucoma before and after surgery
-
Patients willing to receive surgery, blood drawl and OPD follow up
-
no previous corneal epithelial defect or disease
Exclusion Criteria:
-
Limbus defect
-
postsurgical use of other eye drops
-
incomplete eyelid closure
-
glaucoma
-
unable to be followed up postoperatively
-
poor visual acuity or poor prognostic visual acuity
-
corneoneuropathy
-
severe dry eye syndrome
-
pregnant
-
receive eye surgery within one month after the previous eye surgery
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Taiwan University Hospital, department of Ophthalmology | Taipei | Taiwan | 10047 |
Sponsors and Collaborators
- National Taiwan University Hospital
Investigators
- Principal Investigator: Wei-Li Chen, MD, PhD, National Taiwan University Hospital, department of Ophthalmology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 200803017M